In summary, we demonstrated that VDR is needed for BCR::ABL1-driven CML progression and that targeting VDR has the potential to suppress the proliferation of CML cells independent of BCR::ABL mutations and eliminate LSCs. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.